MedTrace Logo

Prospective Registry of Patients With Pancreas Adenocarcinoma Resectable and Borderline

NCT05514171 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2024-06-07

No results posted yet for this study

Summary

Unlike other types of gastrointestinal tumors, there is controversial evidence of the efficacy of neoadjuvant therapy in patients with borderline and resectable adenocarcinoma (ADK) of the pancreas, the objective of this study is to perform a "snapshot" of the usual practice in our setting in terms of neoadjuvant therapy in ADK, both in terms of the different regimens used as well as the results in terms of morbidity, mortality and survival.

Likewise, in a second phase, a prospective registry of patients included in the neoadjuvant regimen for both resectable and borderline ADK diagnosed in Catalonia will be launched, which will provide us with valuable information to try to answer open questions in the context of borderline and resectable ADK treatment.

Conditions

  • Chemotherapy Effect
  • Pancreas Cancer

Interventions

PROCEDURE

Neoadyuvant therapy

Patients of group neoadyuvant therapy will receive any chemotherapy treatment before surgery

Sponsors & Collaborators

  • Hospital del Mar

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2023-06-30
Completion
2023-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05514171 on ClinicalTrials.gov